Telomir Pharmaceuticals Submits IND for Lead Cancer Drug Telomir-1 in Triple-Negative Breast Cancer
Summary
Telomir Pharmaceuticals announced the submission of an IND application to the FDA for its lead investigational candidate, Telomir-1, for the treatment of advanced and metastatic Triple-Negative Breast Cancer.
Key Events
-
IND Application Submitted
Telomir Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn).
-
Targeting Triple-Negative Breast Cancer
The lead candidate, Telomir-1, is intended for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).
-
Phase 1/2 Trial Planned
Subject to FDA clearance, the company plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1 as an oral monotherapy in TNBC patients.
-
Preclinical Efficacy and Safety
Preclinical studies showed Telomir-Zn reduced tumor growth and metastatic dissemination in TNBC models, with no treatment-related adverse or dose-limiting toxicities observed in GLP safety studies.
Analysis
Telomir Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn), its lead candidate for advanced and metastatic Triple-Negative Breast Cancer. This is a critical milestone for the company, especially given its recent 'going concern' warning disclosed in the 10-K on March 17, 2026, and the highly dilutive acquisition approved on March 27, 2026. The successful clearance of this IND and subsequent initiation of a Phase 1/2 clinical trial would provide a much-needed positive catalyst and demonstrate progress in their pipeline, which is essential for a small biotech facing financial challenges. Investors should monitor FDA feedback and the planned trial initiation for further developments.
At the time of this filing, TELO was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.2M. The 52-week trading range was $1.05 to $4.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.